Raymond James Financial Services Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Raymond James Financial Services Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,505	Closed	-$398K	–	3410
2023 Q1	$398K	Sell	16,505 -462	-3%	-$5.8K	﹤0.01%	2477
2022 Q4	$179K	Buy	+16,967	New	+$137K	﹤0.01%	2893
2021 Q1	–	Sell	-33,139	Closed	-$561K	–	3288
2020 Q4	$561K	Buy	33,139 +5,990	+22%	+$89.8K	﹤0.01%	2068
2020 Q3	$348K	Sell	27,149 -1,692	-6%	-$21.4K	﹤0.01%	2204
2020 Q2	$407K	Sell	28,841 -12,336	-30%	-$156K	﹤0.01%	2044
2020 Q1	$379K	Sell	41,177 -1,797	-4%	-$23.2K	﹤0.01%	1705
2019 Q4	$640K	Buy	42,974 +11,609	+37%	+$103K	﹤0.01%	1817
2019 Q3	$214K	Buy	31,365 +1,778	+6%	+$18K	﹤0.01%	2454
2019 Q2	$358K	Buy	+29,587	New	+$161K	﹤0.01%	2152

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Raymond James Financial Services Advisors's PRVB Position: Q2 2023 in Review

Raymond James Financial Services Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 16,505 shares — an estimated $398K sold.

Raymond James Financial Services Advisors first reported a position in PRVB in Q2 2019 and held it in 9 quarters. The position peaked at $640K in Q4 2019. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Raymond James Financial Services Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 16,505 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $398K.
Raymond James Financial Services Advisors first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 9 quarters.
Raymond James Financial Services Advisors's Provention Bio, Inc. Common Stock position peaked at $640K in Q4 2019.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2023, filed 25 Jul 2023.